T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Clinical trials for T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental combo aims to boost lymphoma treatment
Disease control Recruiting nowThis phase 2 trial tests whether adding the drug epcoritamab to standard chemotherapy (EPOCH-R) is safe and effective for people with aggressive B-cell non-Hodgkin lymphoma. Epcoritamab is a bispecific antibody that helps the immune system attack cancer cells. The study will enro…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 23, 2026 19:34 UTC
-
New cocktail aims to knock out tough lymphoma
Disease control Recruiting nowThis early-phase trial is testing whether adding the targeted drug polatuzumab vedotin (with or without another drug called glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to se…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 23, 2026 12:09 UTC
-
New drug offers hope for blood cancer patients who Can't have transplants
Disease control Recruiting nowThis study tests a drug called epcoritamab in 30 people with a type of blood cancer (large B-cell lymphoma) that has come back or not responded to treatment. Participants cannot have a stem cell transplant. The goal is to see if the drug can control the cancer for at least 12 mon…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 22, 2026 12:06 UTC
-
New injection shows promise for tough lymphoma cases
Disease control Recruiting nowThis early-stage trial tests a new biologic drug called PIC1 injection in 18 adults with relapsed or refractory B-cell non-Hodgkin lymphoma. The main goal is to check safety and find the right dose. Researchers will also see if the drug can shrink tumors. It is too soon to know i…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jun 22, 2026 11:54 UTC
-
New combo therapy offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests whether adding the drug pembrolizumab to standard CAR-T cell therapy can improve outcomes for people with a rare type of lymphoma (PMBCL) that has returned or not responded to prior treatment. About 35 adults will receive the combination and be monitored for 6 mo…
Matched conditions: T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC